Effect of Erythromycin on Albendazole-Induced Teratogenicity in Pregnant Rats

Article history: Received: 1 June 2012 Accepted: 24 Oct 2012 Available online: 18 Nov 2012 ZJRMS 2013; 15(5): 43-46 Background: Albendazole is utilized as an anthelmentic agent. One its side effect is teratogenicity. This effect apparently is related to its metabolites especially albendazole sulfoxid. The aim of present study was evaluation effect of erythromycin (as enzyme inhibitor in biotransformation) on albendazole biotransformation and consequently fetal malformation. Materials and Methods: Four groups of female pregnant wistar rats (8 rats each group) were used. First group received normal saline (as control group). A single oral dose 30 mg/kg of albendazole was administered to rats on day 10 of gestation in group 2. Rats in group 3 received albendazole similar group 2 and erythromycin at dose 60 mg/kg. Rats in group 4 received only erythromycin on day 10 of gestation. The rats were euthanatized on day 20 of gestation. The skeletal malformation of fetus was studied by stereomicroscope after staining by Alizarin red-Alcian blue Results: The length and weight of fetuses were significantly decreased by albendazole but erythromycin did not prevent this effect. In group that received only erythromycin, the length and weight of fetuses was similar to control group. Erythromycin decreased albendazole effect on weight of placenta. There was an increase in resorption by erythromycin when co-administrated with albendazole. The incidence of skeletal malformations (mostly of the limbs, vertebrae and palate) decreased significantly by erythromycin when co-administrated with albendazole. .

[1]  S. Arıkan,et al.  Use of albendazole sulfoxide, albendazole sulfone, and combined solutions as scolicidal agents on hydatid cysts (in vitro study). , 2009, World journal of gastroenterology.

[2]  B. Källén,et al.  Is erythromycin therapy teratogenic in humans? , 2005, Reproductive toxicology.

[3]  Ruberval Armando Lopes,et al.  Efectos del Albendazol en el Hígado de Feto de Rata: Estudios Morfológico y Morfométrico , 2005 .

[4]  J. Sallovitz,et al.  Placental and fetal toxicity of albendazole sulphoxide in Wistar rats. , 2003, Veterinary and human toxicology.

[5]  J. Ruberte,et al.  Albendazole sulphoxide enantiomers in pregnant rats' embryo concentrations and developmental toxicity. , 2003, Veterinary journal.

[6]  H. Celik,et al.  Effects of erythromycin on pregnancy duration and birth weight in lipopolysaccharide-induced preterm labor in pregnant rats. , 2002, European Journal of Obstetrics, Gynecology, and Reproductive Biology.

[7]  S. Nardiello,et al.  [Risks of antibacterial agents in pregnancy]. , 2002, ˜Le œInfezioni in medicina.

[8]  J. Horton.  Albendazole: a review of anthelmintic efficacy and safety in humans , 2000, Parasitology.

[9]  J. Olsen,et al.  A population-based case-control teratologic study of oral erythromycin treatment during pregnancy. , 1999, Reproductive toxicology.

[10]  Gur Sl.  Erythromycin: drug interactions. , 1997 .

[11]  S. Gurevitz.  Erythromycin: drug interactions. , 1997, Journal of dental hygiene : JDH.

[12]  A. Mantovani,et al.  Effects observed on gestational day 13 in rat embryos exposed to albendazole. , 1995, Reproductive toxicology.

[13]  Y. Cruz.  Laboratory Exercises in Developmental Biology , 1993 .

[14]  R. C. Parish,et al.  Albendazole : a comparison of relay embryotoxicity with embryotoxicity of individual metabolites. , 1981, Annales de recherches veterinaires. Annals of veterinary research.

[15]  L. Sabath,et al.  Transplacental passage of erythromycin and clindamycin. , 1973, The New England journal of medicine.

[16]  N. Booth,et al.  Veterinary Pharmacology and Therapeutics , 1885, Glasgow Medical Journal.